https://ctrk.klclick.com/l/01M2ZDVD112D4GPK2S1Z8EH3BR_23
QT:{{”
Elysium Abstract
…
An AI-designed drug sent six aging clocks backward
In a 12-week phase 2a trial, an AI-designed drug for idiopathic pulmonary fibrosis reduced predicted biological age across six protein-based aging clocks in 42 participants. The findings don’t prove the drug slows aging, but they point to a new way to study it. “This is one of the few concrete examples of a drug largely designed with generative AI,” says Mark Gerstein, Ph.D., Albert L. Williams Professor of Biomedical Informatics at Yale and a member of Elysium’s Scientific Advisory Board. “Moreover, it’s impressive to see how AI was used throughout the whole drug-development process, from upstream target finding to analyzing the downstream trial for results related to longevity.” He adds: “This last use has great promise for aging research, showing how conventional disease trials can be made into dual-purpose designs suitable for studying longevity.” (Nature Biotechnology)
“}}
